Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Complexity and clinical significance of drug–drug interactions (DDIs) in oncology: challenging issues in the care of patients regarding cancer-associated thrombosis (CAT)
Nikolaos Tsoukalas, Norman Brito-Dellan, Carme Font, et al.
Supportive Care in Cancer (2022) Vol. 30, Iss. 10, pp. 8559-8573
Open Access | Times Cited: 19

Showing 19 citing articles:

Oral Anticoagulants Beyond Warfarin
Renske H. Olie, Kristien Winckers, Bianca Rocca, et al.
The Annual Review of Pharmacology and Toxicology (2023) Vol. 64, Iss. 1, pp. 551-575
Open Access | Times Cited: 15
In Vivo pharmacokinetic interactions of ribociclib with rivaroxaban and apixaban in rats: implications for increased drug exposure and dose adjustments
Zihan Liu, Wenyu Du, Qimin Wang, et al.
Frontiers in Pharmacology (2025) Vol. 16
Open Access
MecDDI: Clarified Drug–Drug Interaction Mechanism Facilitating Rational Drug Use and Potential Drug–Drug Interaction Prediction
Wei Hu, Wei Zhang, Ying Zhou, et al.
Journal of Chemical Information and Modeling (2023) Vol. 63, Iss. 5, pp. 1626-1636
Closed Access | Times Cited: 11
Treating cancer-associated venous thromboembolism: a practical approach
Eric Van Cutsem, Isabelle Mahé, Enriqueta Felip, et al.
European Journal of Cancer (2024) Vol. 209, pp. 114263-114263
Closed Access | Times Cited: 4
Enzalutamide: Understanding and Managing Drug Interactions to Improve Patient Safety and Drug Efficacy
Brandon Lennep, Jesse Mack, Srinivasu Poondru, et al.
Drug Safety (2024) Vol. 47, Iss. 7, pp. 617-641
Open Access | Times Cited: 3
Lung Cancer Related Thrombosis (LCART): Focus on Immune Checkpoint Blockade
Andriani Charpidou, Grigoris Gerotziafas, Sanjay Popat, et al.
Cancers (2024) Vol. 16, Iss. 2, pp. 450-450
Open Access | Times Cited: 2
SEOM clinical guidelines on venous thromboembolism (VTE) and cancer (2023)
Laura Ortega, Francisco José Pelegrín Mateo, Rut Porta Balanyà, et al.
Clinical & Translational Oncology (2024) Vol. 26, Iss. 11, pp. 2877-2901
Open Access | Times Cited: 2
Mitigating the Risk of Drug Interactions in Cancer Patients Taking Oral Anticancer Agents: The Role of a Multidisciplinary Team-Based Medication Reconciliation
Jorge Rodrigues, Paula A. A. P. Marques, Catarina Gomes, et al.
Cureus (2023)
Open Access | Times Cited: 4
Cardio-Oncology: A New Discipline in Medicine and Its Relevance to Hematology
Andreas Spannbauer, Jutta Bergler‐Klein
Hämostaseologie (2024) Vol. 44, Iss. 04, pp. 255-267
Open Access | Times Cited: 1
The Role of Injectables in the Treatment and Prevention of Cancer-Associated Thrombosis
Mariasanta Napolitano, Sergio Siragusa
Cancers (2023) Vol. 15, Iss. 18, pp. 4640-4640
Open Access | Times Cited: 3
The roles of CYP2C19 and CYP3A4 in the in vitro metabolism of β‐eudesmol in human liver: Reaction phenotyping and enzyme kinetics
Nadda Muhamad, Kesara Na‐Bangchang
Pharmacology Research & Perspectives (2023) Vol. 11, Iss. 6
Open Access | Times Cited: 3
Dilemmas in the Choice of Adequate Therapeutic Treatment in Patients with Acute Pulmonary Embolism—From Modern Recommendations to Clinical Application
Ratko Lasica, Milika Ašanin, Lazar Djukanovic, et al.
Pharmaceuticals (2022) Vol. 15, Iss. 9, pp. 1146-1146
Open Access | Times Cited: 3
Évaluation pharmaceutique des risques de prescription des anticoagulants oraux directs chez le patient atteint de cancer
Jean-Stéphane Giraud, Marion Berge, Johanna Sardelli, et al.
Le Pharmacien Clinicien (2024) Vol. 59, Iss. 4, pp. 452-466
Closed Access
Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants for Japanese Patients With Venous Thromboembolism ― The Primary Results From the KUROSIO Study ―
Norikazu Yamada, Satoshi Tamaru, Michihisa Umetsu, et al.
Circulation Journal (2024) Vol. 88, Iss. 10, pp. 1672-1678
Open Access
Treatment of deep vein thrombosis in cancer patients
Piotr Dunaj, Katarzyna Kołodziejczyk, Tomasz Dzierżanowski
Medycyna Paliatywna (2024) Vol. 16, Iss. 3, pp. 135-149
Open Access
Cost-effectiveness analysis of direct oral anticoagulants versus low-molecular-weight heparin and no thromboprophylaxis in primary prevention of cancer-associated venous thromboembolism in China
Yue Wu, TianChen Yin, Guojin Jian, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access
Drug-drug interactions between direct oral anticoagulants and anticancer drugs: A single center daily practice evaluation of the occurrence, prescriber response, and subsequent thrombotic and bleeding complications in the Netherlands
Evine M. Appelman, Emily S.L. Martens, D.M. Burger, et al.
Thrombosis Research (2024) Vol. 245, pp. 109232-109232
Closed Access
A new method to quantify the effect of co-medication on the efficacy of abiraterone in metastatic castration-resistant prostate cancer patients
B. Fekete, Lili Bársony, Krisztina Bíró, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access
Direct oral anticoagulants in prevention and treatment of cancer-associated thrombosis
Darko Antić, Sofija Šarac, Vladimir Otašević
Galenika Medical Journal (2022) Vol. 1, Iss. 4, pp. 105-112
Open Access
Page 1

Scroll to top